Prellis advances its goal of using 3D holographic printing to create organoids for research and development – recently closing a $10.5m investment round to further develop its technology, which accelerates drug screening, says CEO.
As 3D printing technology continues to develop, it is becoming more disruptive to the pharmaceutical manufacturing industry as its value in drug delivery becomes apparent, according to IDTechEx.
This week in-PharmaTechnologist attended AAPS PharmSci360 in Washington, D.C. where discussions and thought-provoking ideas bounced across sessions – here, we highlight some of the most significant.
The US FDA has drawn industry attention to the potential of 3D printing and continuous manufacturing, which it says could “improve drug quality, address shortages of medicines, lower drug costs, and bring pharmaceutical manufacturing back to the US”.
3D printing can make drug production simpler and cheaper according to a UK expert who says using it for commercial production is about “numbering up” not scaling up.
The US National Institutes of Health (NIH) has launched a 3D Print Exchange which will turn data submitted by the public into files for printing 3D models.
